Edwards Lifesciences Corporation EW announced its decision to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company. This follows Edwards Lifescience ...

Edwards Lifesciences announced Thursday that the California company has completed three first-in-human implants of the company’s transcatheter mitral valve replacement system. But it is not the only ...

Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making it the first minimally invasive, catheter-based treatment that uses a ...

Edwards Lifesciences’ SAPIEN M3 mitral valve replacement system has become the first transcatheter therapy utilizing a transseptal approach to snag FDA approval in the U.S. for the treatment of mitral ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve ...

IRVINE, Calif., December 23, 2025--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing ...

(RTTNews) - Edwards Lifesciences (EW) said it has exercised its option to acquire Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement company, following its initial investment ...

For patients with significant mitral regurgitation (MR) who are unsuitable for surgical intervention or transcatheter edge-to-edge repair (TEER), transcatheter mitral valve replacement (TMVR) appears ...

The positive effect of transapical transcatheter mitral valve replacement (TMVR) in patients with severe symptomatic mitral regurgitation (MR) is sustained at 2 years, according to follow-up data on ...

Edwards Lifesciences, a leading global structural heart innovation company, announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal ...